Incyte Reports Positive Phase 3 Results for Retifanlimab in NSCLC
Incyte has announced promising results from the Phase 3 POD1UM-304 trial evaluating retifanlimab (Zynyz®), a PD-1-targeting monoclonal antibody, in combination with platinum-based chemotherapy for adults with previously untreated metastatic non-small…
Blueprint Medicines Showcases Leadership in Systemic Mastocytosis at 2024 ASH Meeting
Blueprint Medicines Corporation presented compelling new data at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing the long-term benefits of AYVAKIT® (avapritinib) in treating systemic mastocytosis (SM). These…
AbbVie Releases Report on Mental Health in Underrepresented CLL Patients
AbbVie has unveiled key findings from its latest Emotional Impact Report (EIR), offering insights into the mental health challenges faced by patients with chronic lymphocytic leukemia (CLL). For the first…
An Innovative Approach to Efficient Anti-Cancer Drug Synthesis
The Horner-Wadsworth-Emmons (HWE) reaction is a fundamental reaction in organic chemistry, widely used to create conjugated carbonyl compounds. Conjugated carbonyl compounds are used in many industries for synthesizing perfumes, plastics,…
Stoke Therapeutics Presents Data Supporting Zorevunersen as Treatment for Dravet Syndrome
Stoke Therapeutics has announced new data from its Phase 1/2a and open-label extension (OLE) studies on zorevunersen, a potential disease-modifying treatment for Dravet syndrome. The data revealed significant and lasting…
Alithea Genomics Unveils Full-Length DRUG-Seq to Enhance Transcriptomics in Drug Discovery
Alithea Genomics, a leading innovator in large-scale RNA sequencing and transcriptomics, has unveiled its latest technological advancement: the MERCURIUS™ Full-Length DRUG-seq library preparation platform. This new solution represents a groundbreaking…
Children’s Hospital Los Angeles Marks 100th Retinal Gene Therapy Procedure
At Children’s Hospital Los Angeles Dr. Aaron Nagiel, MD, PhD, has witnessed firsthand the profound impact of retinal gene therapy on children with Leber congenital amaurosis (LCA), a rare genetic…
IMFINZI Receives Priority Review in US for Muscle-Invasive Bladder Cancer
AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) and granted it Priority Review. The application seeks approval…
Senegal and Rwanda Attain WHO Maturity Level 3 for Medicines Regulation
Senegal and Rwanda have joined an elite group of African nations by achieving Maturity Level 3 (ML3) status in the World Health Organization’s (WHO) global classification of national regulatory authorities.…
Webinar Leveraging Digital and Analytics Tools in Mpox Response
Between January 2022 and October 2024, over 120 countries reported cases of mpox, marking a significant multi-country outbreak that impacted all WHO regions. In response, public health professionals convened in…
LEQEMBI (Lecanemab) Gains Approval in Mexico for Early Alzheimer’s Treatment
Eisai and Biogen Inc. have announced that Mexico’s Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has approved LEQEMBI (lecanemab), a humanized monoclonal antibody, for the treatment of early…
EU Approves Novo Holdings’ Catalent Acquisition and Novo Nordisk’s Site Purchase
Today, the European Commission officially approved the acquisition of Catalent, Inc. by Novo Holdings A/S, a deal that will further expand the capabilities of the Novo Group. Catalent, a global…